All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
National Institute of Pharmaceutical R&D Co. Ltd. has identified Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of cancer and viral infections.
Chongqing Fochon Pharmaceuticals Co. Ltd. has divulged apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer, Addison’s disease, allergy, asthma, atherosclerosis, ankylosing spondylitis, Alzheimer’s disease and systemic lupus erythematosus, among others.
Shanghai Euregen Biopharma Co. Ltd. has divulged menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer, autoimmune disease, diabetes and nonalcoholic fatty liver disease).
Ubix Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bruton tyrosine kinase (BTK) targeting moiety via linker acting as BTK degradation inducers reported to be useful for the treatment of cancer and autoimmune disease.
Celros Biotech Co. Ltd. has synthesized cytochrome b-245 heavy chain (CYBB; NOX2) and NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, Alzheimer’s disease, cirrhosis, diabetes, cancer, glomerulonephritis, psoriasis and rheumatoid arthritis, among others.
Sanford-Burnham Medical Research Institute has disclosed baculoviral IAP repeat-containing protein 7 (BIRC7; ML-IAP) inhibitors reported to be useful for the treatment of cancer.